Physician profile
Kenneth E Vargas
NPI 1639249774
$13,555.04
in general payments reported to CMS, 2019-2025
54 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,845 · 2020: $1,420 · 2021: $2,148 · 2022: $2,393 · 2023: $2,788 · 2024: $1,916 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,750.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,211.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,321.83 | 2019-2025 | |
| Amgen INC. | $1,024.98 | 2019-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $997.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $883.20 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $855.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $822.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $682.59 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $467.96 | 2019-2024 | Gardasil, Gardasil 9, Verquvo |
| Novartis Pharmaceuticals Corporation | $462.70 | 2019-2023 | |
| Astellas Pharma US INC | $444.19 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $376.42 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.55 | 2019-2025 | Jardiance, Jascayd, Ofev |
| Biohaven Pharmaceutical Holding Company Ltd. | $231.60 | 2022 | |
| Esperion Therapeutics, INC. | $205.14 | 2020-2023 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.